Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
about
Recent progress in pancreatic cancerSystemic Chemotherapy in Advanced Pancreatic CancerCurrent therapeutic strategies for advanced pancreatic cancer: A review for cliniciansImmunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsAdvances in systemic therapy for advanced pancreatobiliary malignanciesSystemic treatment for inoperable pancreatic adenocarcinoma: review and updatePancreatic cancer: New hopes after first line treatmentAdvances in chemotherapy for pancreatic cancerPancreatic cancer: yesterday, today and tomorrow.DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data BasePhase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity.Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response.Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinomaFOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM studyDuctal pancreatic adenocarcinoma.Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.Current and future systemic treatment options in metastatic pancreatic cancer.First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract.Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.S-1 in the treatment of pancreatic cancer.Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies.Viral vector-based therapeutic cancer vaccinesA phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialEarly recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis.Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer.Clinical evaluation of TRICOM vector therapeutic cancer vaccinesPancreatic Cancer: Progress in Systemic Therapy.Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabineOxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line?
P2860
Q24626346-46106DB0-9DB6-434B-BFB0-82753060B1B8Q26750440-8BBBA5F4-4A61-4DF0-BA0C-8D6A132EF741Q26767041-3FBB4F39-6066-4D93-BAEE-C91BB6C08C75Q26781538-5ADCA3AA-4231-4F7E-8B74-03A6CA7B1F4FQ26822703-E21819FF-E3A1-4093-9AAC-E753C2554E29Q26830913-F9974CF4-2669-475F-A4FC-14CE744B68C2Q28067055-74F4434D-0516-49CF-A913-BA75D9216DB5Q28085711-CD1BB14A-20BF-42A1-8A18-9E4B2A69B44AQ30250026-23582DD3-5E7C-4DE1-A432-F9E1E91C7D18Q30315797-428EAD9A-FBA0-41C9-AEE1-A4F1C4F7CECAQ30978290-C8A2CA67-57BD-4283-8B58-BD70A3E76E4EQ33415850-EFA42FBE-FDC1-4D2F-AAD7-CC34E5246FB3Q33425869-5474534B-2FB9-459D-A3BD-4E94E4B2C07FQ33426575-AA31CBBC-FAA8-491A-B2B0-2FECE30EE8BCQ33428382-72671A8F-5FD9-4728-BAE6-5E54DE3ACFA6Q33443909-3EADDC38-716F-4FE5-895C-F7E2E9FF7A53Q33606097-0878C483-0E3A-41F1-ACDA-F276E62FF723Q33672571-CB08A1F5-8D64-4ADC-B15B-D77345B813FAQ33751227-9B46BA63-60F9-43CD-8209-C215BC303BB7Q33823212-94B546C1-A301-4FA2-89F6-98ACE9F85AAEQ33832655-4D5367D8-794D-4CF0-9067-34803C6F5F9CQ33913549-89DF792B-A3FC-4F28-BCE7-BFD2286B91BFQ33948033-C129BC8F-1416-4737-8271-F521B1A0F2AEQ34008520-331E9652-5374-4346-9840-FB1001975F7CQ34301038-C1157EB9-7C7D-46D6-942C-4C578BDEF8A9Q34404088-9AFDE839-1699-4AA3-847A-0EFD1A88A8DFQ34431614-FB33C505-1945-468A-B94E-22F07F8DB2FBQ34467156-16E7C1F3-235A-4315-AF0E-E7013DD4F00DQ35136815-4798E12A-7111-4452-85AE-36815B9707CCQ35515080-B7228266-9907-441E-ACF6-59C1180134D4Q35703105-1CF95197-EC13-4E9D-BD5F-0C337D5627ACQ35703129-091D748F-05C9-41B3-897F-29B0A7E82891Q35828693-D7819AEC-B73D-409C-80D4-8EE97A024838Q35890548-2413CE05-5B52-434E-9824-E5C98565A57FQ36062637-D18B8531-B59A-4EF9-9CAF-293A827DA450Q36093374-10A092CC-8F32-460F-99B6-E48014E789D4Q36099965-2B5FF020-2605-468D-A10D-DEEDDC5C257BQ36344551-8EC91ED5-2D23-4F83-9410-888C45BF2AAAQ36595053-E6C7498C-C9D6-4FE8-BF39-6581BA1C2597Q36682682-BA20FBD1-0D4C-4503-80F6-158FAE1D1F7F
P2860
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Best supportive care (BSC) ver ...... the German CONKO-study group.
@ast
Best supportive care (BSC) ver ...... the German CONKO-study group.
@en
Best supportive care (BSC) ver ...... the German CONKO-study group.
@nl
type
label
Best supportive care (BSC) ver ...... the German CONKO-study group.
@ast
Best supportive care (BSC) ver ...... the German CONKO-study group.
@en
Best supportive care (BSC) ver ...... the German CONKO-study group.
@nl
prefLabel
Best supportive care (BSC) ver ...... the German CONKO-study group.
@ast
Best supportive care (BSC) ver ...... the German CONKO-study group.
@en
Best supportive care (BSC) ver ...... the German CONKO-study group.
@nl
P2093
P1476
Best supportive care (BSC) ver ...... the German CONKO-study group.
@en
P2093
Bernd Dörken
Hanno Riess
Helmut Oettle
Ingo Schwaner
Jens Stieler
Jörg Seraphin
Mathias Adler
Uwe Pelzer
P304
P356
10.1016/J.EJCA.2011.04.011
P577
2011-05-10T00:00:00Z